The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

The executives packed into the room, eager to hear the good news on their blockbuster-to-be. Medivation, a California startup, was developing a treatment for Alzheimer’s disease, and pivotal results from a major clinical trial were finally available. An earlier study, conducted in Russia, had generated what Alzheimer’s experts hailed as the best results the field had…


The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer
The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

Comments

Loading Facebook Comments ...
Loading Disqus Comments ...